Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects

Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ9‐THC in Cannabis Users

“…These findings are likely not surprising to professionals with experience administering oral Δ 9 ‐THC to clinical research subjects or patients receiving treatment, but published reports from controlled studies illustrating this variability are scarce. Related, these results support the therapeutic use of other orally available cannabinoids such as nabilone, or alternative oral formulations of Δ 9 ‐THC with more favorable pharmacokinetic profiles . Lastly, the use of such an extensive range of doses permitted the demonstration of a partial agonist profile for Δ 9 ‐THC in humans.…”

Cannabinoid Receptor Agonist Namisol Does Not Affect Cytokine Levels In Chronic Pancreatitis Patients

“…Given the promising eff ects of CB agonists on visceral pain modulation in rodent models of chronic pancreatitis ( 8 ), we will eagerly await the fi nal results of Dr Utomo and colleagues' study and hope that it sheds further light on an option for analgesia for these patients without the side eff ects of narcotics and the risks of endoscopic therapy. ( 2 ). It is encouraging to hear of a novel addition to the body of human studies investigating the potential therapeutic application of cannabinoids to human disease-in this case, the use of purifi ed Δ9-THC (Namisol ® ) in a clinical trial for chronic pancreatitis.…”

Nabilone in inflammatory pain: to be or not to be

“…Clinical trials have been performed, in the past decade because of the new availability of synthetic cannabinoid compounds (e.g. dronabinol, nabilone, Sativex spray (GW Pharmaceuticals, Salisbury, UK), Namisol (Echo Pharmaceuticals, Jonkerbosplein, The Netherlands) …”